Skip to main content

Table 1 Baseline characteristics of patients (n = 272)

From: Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

Characteristic n (%)
Age at diagnosis, years, median [IQR] 63.2 [52.0;73.0]
Age at metastasis, years, median [IQR] 67.0 [55.0;75.0]
Male sex, n (%) 172 (63.2)
Basal LDH, n (%)
 Normal 171 (62.87)
 Increased 79 (29)
 Not available 22 (8.1)
Mutational status
 BRAF/NRAS wild type 145 (53.3)
 NRAS mutated 127 (46.7)
N of metastatic sites < 3, n (%) 169 (62.1)
Site of melanoma
 Cutaneous 210 (77.2)
 Mucosal 19 (7)
 Ocular 14 (5.1)
 Unknown 29 (10.7)
Prior adjuvant therapy 20 (7.3%)
ECOG PS
 0 192 (70.6)
 1 78 (28.7)
 2 2 (0.7)
Stage at metastatic disease (AJCC VIII edition)
 M1a 66 (24.3)
 M1b 77 (28.3)
 M1c 102 (37.5)
 M1d 27 (9.9)
First line therapy
Anti-PD-1 209 (76.8)
Anti-CTLA-4 57 (20.9)
Anti-PD-1 + Anti-CTLA-4 6 (2.2)
  1. IQR interquartile range